Amedisys, Inc. (NASDAQ: AMED) Terminates Purchase Agreement with VCG Luna

Amedisys, Inc. filed a Form 8-K with the Securities and Exchange Commission (SEC) on January 3, 2025, announcing the termination of a purchase agreement. The agreement, initially entered into on June 28, 2024, involved Amedisys, UnitedHealth Group Incorporated, and their subsidiaries as sellers, and VCG Luna, LLC as the purchaser.

UnitedHealth Group delivered a Termination Notice to VCG Luna on January 3, 2025, resulting in the termination of the VCG Purchase Agreement. Following this termination, UnitedHealth Group and VCG Luna reached an agreement on January 8, 2025, which included mutual releases of all claims related to the VCG Purchase Agreement between the parties.

The filing also included a cautionary statement regarding forward-looking statements, emphasizing uncertainties and risks related to the terminated agreement and the potential impact on Amedisys’s business operations and financial outcomes.

Forward-looking statements in the filing highlighted the complexities and uncertainties surrounding the termination of the agreement, potential regulatory hurdles, costs associated with the agreement, and the shift of management’s focus towards completing the transaction.

The filing reinforced that any forward-looking statements made were based on information available at the time and cautioned against relying solely on such statements due to the inherent uncertainties and risks involved.

Amedisys, Inc.’s President and Chief Executive Officer, Richard Ashworth, signed the report on January 8, 2025, on behalf of the company.

For more information regarding the terminated agreement and the subsequent arrangements between UnitedHealth Group and VCG Luna, interested parties are encouraged to refer to the SEC filing made by Amedisys, Inc.

Please note that the information provided in the filing is based on the details disclosed by Amedisys, Inc. and the SEC filing itself.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Amedisys’s 8K filing here.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.